How to manage regulatory variations of a Marketing Authorisation (MA)?
Managing post-authorisation changes is a major regulatory challenge. Any modification made after obtaining the Marketing Authorisation (MA), such as the addition of suppliers, raw materials, etc, requires a new regulatory assessment. The methodical approach to these variations directly conditions the continued marketing of the drugs concerned within the European Union.
To better understand the initial prerequisites, our documentation on obtaining a marketing authorisation for a new medicinal product sets out the essential foundations of this process.
Alhena Consult supports pharmaceutical and biotechnology companies through the complexities inherent in these changes. Its expertise in regulatory affairs covers the entire lifecycle, from early development to post-approval activities.
Understanding regulatory MA variations
Regulatory variations refer to changes made to the initial terms of a MA. These modifications are part of the medicine’s lifecycle and follow a precise classification as defined by Regulation (EC) No 1234/2008 of the European Commission.
There are three main types of variations:
- Type IA variations: these have minimal or no impact on the quality, safety, or efficacy of the product. They can be implemented without prior approval.
- Type IB variations: these minor changes do not meet the criteria for Type IA or Type II. They may involve updates to the SmPC (Summary of Product Characteristics). This category also includes “unforeseen” variations as per Article 5 of the Regulation.
- Type II variations: these may significantly impact the quality, safety, or efficacy of the product and therefore require a thorough evaluation.
The procedural framework applied depends on the type of MA involved.
Regulatory variation management process at Alhena Consult
Alhena Consult has developed a structured approach to managing regulatory MA variations:
- Analysis of the proposed variation to determine its regulatory classification.
- ptimisation of submissions by grouping compatible variations, reducing evaluation timelines.
- For MA holders with multiple authorisations, simultaneous submission of a given change across several MAs.
- Preparation of comprehensive and compliant documentation.
- Proactive follow-up of submissions and coordination of communication with competent authorities during the evaluation phase.
This structured strategy helps reduce approval timelines and mitigate the risk of rejection.
Regulatory challenges and best practices
In the context of MA variations, maintaining product conformity represents a real challenge for pharmaceutical companies.
Post-MA vigilance points:
- Continuous evolution and multiplicity of national and international standards requiring constant regulatory watch.
- High volume of documentation to be maintained and updated, necessitating a robust document management system.
- Involvement of numerous departments depending on the type of change (R&D, production, quality assurance, pharmacovigilance, regulatory affairs), requiring effective cross-functional coordination.
Concrete approaches to overcome regulatory and organizational challenges:
Active regulatory monitoring helps track the evolution of requirements. This effort is strengthened by professionals trained in EU regulations.
Harmonisation of procedures, along with mutual recognition, supports effective management of divergences across member states.
A centralized documentation system ensures data reliability, while rigorous validation processes enable continual updates.
Cross-functional steering committees and collaborative tools enhance coordination between R&D, production, quality assurance, pharmacovigilance, and regulatory affairs.
Alhena Consult’s approach integrates these optimisation levers to ensure compliance while streamlining processes.
Upcoming regulatory changes in MA variation classification
European authorities are preparing to revise the regulatory framework surrounding the classification of post-authorisation variations.
The goal is to clarify classification criteria (IA, IB, II), modernise procedures, and align more closely with international approaches, particularly ICH Q12.
The Delegated Regulation (EU) 2024/1701, effective since January 1, 2025, has already simplified the handling of minor variations, which can now be grouped in an annual report. It also relaxed requirements for certain biological products, previously classified automatically as major variations.
In parallel, the European Commission is working on a new guideline, expected to be finalised in 2025, which will provide detailed classification categories and corresponding procedures. This update will incorporate ICH Q12 principles, promoting a risk-based approach and distinguishing between changes that require notification versus prior approval.
Grouping mechanisms will also be expanded to allow for a single submission covering several similar changes across multiple MAs. This evolution is part of a broader trend toward regulatory simplification, efficiency, and global convergence, also promoted by the WHO.
Pharmaceutical companies are therefore encouraged to prepare now by maintaining an active regulatory watch, optimizing document management, and adapting internal processes to align with this more flexible, coherent framework.
Mastering MA variations: a strategic Lever for the pharmaceutical industry
A methodical approach to managing regulatory MA variations ensures the continuity of product marketing. Indeed, a structured, anticipatory, and compliant management of these changes not only supports regulatory compliance but also optimizes approval timelines and resource allocation.
As the pharmaceutical regulatory environment becomes increasingly complex and dynamic, companies must strengthen their internal regulatory affairs abilities. Cross-functional integration of expertise has become a strategic imperative to anticipate regulatory shifts effectively.
By leveraging the specialized expertise of Alhena Consult, companies can transform regulatory constraints into competitive advantages.
